Evidence map›Paper›PMID 36319976›Full record

ArticleBiology direct2022

Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer.

Di Wang, Junye Liufu, Qiyuan Yang, Shengqun Dai, Jiaqi Wang, Biao Xie

Open access · goldAbstract read
In one paragraph

Article in Biology direct, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Translational cancer research · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer.International journal of molecular sciences · 2023
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Di Wang *Department of Gastroenterology, People's Hospital of Longhua, NO.38 Jinglong Construction Road, Longhua District, 518109, Shenzhen, P.R. China.
Junye Liufu *Department of Gastroenterology, People's Hospital of Longhua, NO.38 Jinglong Construction Road, Longhua District, 518109, Shenzhen, P.R. China.
Qiyuan YangDepartment of Gastroenterology, People's Hospital of Longhua, NO.38 Jinglong Construction Road, Longhua District, 518109, Shenzhen, P.R. China.
Shengqun DaiDepartment of Gastroenterology, People's Hospital of Longhua, NO.38 Jinglong Construction Road, Longhua District, 518109, Shenzhen, P.R. China.
Jiaqi WangDepartment of Gastroenterology, Guangzhou First People's Hospital, 511458, Guangzhou, P.R. China.
Biao XieDepartment of Gastroenterology, People's Hospital of Longhua, NO.38 Jinglong Construction Road, Longhua District, 518109, Shenzhen, P.R. China. xiebiaohxq@163.com.
Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is one of the most common malignant neoplasms worldwide. Although marker genes associated with CRC have been identified previously, only a few have fulfilled the therapeutic demand. Therefore, based on differentially expressed genes (DEGs), this study aimed to establish a promising and valuable signature model to diagnose CRC and predict patient's prognosis.

methodsThe key genes were screened from DEGs to establish a multiscale embedded gene co-expression network, protein-protein interaction network, and survival analysis. A support vector machine (SVM) diagnostic model was constructed by a supervised classification algorithm. Univariate Cox analysis was performed to construct two prognostic signatures for overall survival and disease-free survival by Kaplan-Meier analysis, respectively. Independent clinical prognostic indicators were identified, followed by univariable and multivariable Cox analysis. GSEA was used to evaluate the gene enrichment analysis and CIBERSORT was used to estimate the immune cell infiltration. Finally, key genes were validated by qPCR and IHC.

resultsIn this study, four key genes (DKC1, FLNA, CSE1L and NSUN5) were screened. The SVM diagnostic model, consisting of 4-gene signature, showed a good performance for the diagnostic (AUC = 0.9956). Meanwhile, the four-gene signature was also used to construct a risk score prognostic model for disease-free survival (DFS) and overall survival (OS), and the results indicated that the prognostic model performed best in predicting the DFS and OS of CRC patients. The risk score was validated as an independent prognostic factor to exhibit the accurate survival prediction for OS according to the independent prognostic value. Furthermore, immune cell infiltration analysis demonstrated that the high-risk group had a higher proportion of macrophages M0, and T cells CD4 memory resting was significantly higher in the low-risk group than in the high-risk group. In addition, functional analysis indicated that WNT and other four cancer-related signaling pathways were the most significantly enriched pathways in the high-risk group. Finally, qRT-PCR and IHC results demonstrated that the high expression of DKC1, CSE1L and NSUN5, and the low expression of FLNA were risk factors of CRC patients with a poor prognosis.

conclusionIn this study, diagnosis and prognosis models were constructed based on the screened genes of DKC1, FLNA, CSE1L and NSUN5. The four-gene signature exhibited an excellent ability in CRC diagnosis and prognostic prediction. Our study supported and highlighted that the four-gene signature is conducive to better prognostic risk stratification and potential therapeutic targets for CRC patients.

Indexed as

Colorectal NeoplasmsGene Expression Regulation, NeoplasticBiomarkers, TumorCell Cycle ProteinsHumansKaplan-Meier EstimateNuclear ProteinsPrognosisBiomarkers, TumorCell Cycle ProteinsDKC1 protein, humanNuclear ProteinsColorectal cancerDiagnostic modelDifferentially expressed genesPrognostic model

Identifiers

PMID36319976
PMCPMC9628086
OpenAlexW4307831201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.